According to statistics from the Particle Therapy Co‑Operative Group (PTCOG), by 2021, more than 260,000 patients worldwide had received proton or heavy‑ion therapy. The number of proton centers grew from 1 in 1990 to over 100 today, and is still rising rapidly. Proton therapy has become a major global trend in precision cancer radiotherapy.

ACC-NK (Antibody-Cell Conjugated NK) is an innovative immune cell therapy targeting solid tumors and hematological malignancies. With non-viral vector and non-gene editing technology, it provides highly effective targeted tumor killing via 5T4, Trop-2, CD33-CLL1 dual-targeting, and synergistic combination therapy with ADC, radiotherapy and chemotherapy.